Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
Overall Survival
46%
Resectability
34%
Older Patients
29%
Colorectal Cancer
27%
Resection
24%
Quality of Life
24%
Metastasectomy
23%
Systemic Therapy
22%
YKL-40
20%
Cardiotoxicity
20%
Interleukin-6
20%
Palliative Chemotherapy
20%
Fluoropyrimidine
20%
Oxaliplatin
20%
Local Ablative Therapy
19%
5-fluorouracil (5-FU)
17%
Metastasis
16%
Overall Survival Rate
16%
Adjuvant Chemotherapy
15%
Prognostic Value
14%
Capecitabine
14%
Liver Metastasis
14%
Carbohydrate Antigen 19-9 (CA19-9)
13%
Subgroup Analysis
13%
Disease-free Survival
13%
Multidisciplinary Team
13%
Adjuvant Therapy
12%
Tumor
12%
5-year Survival
12%
Bevacizumab
12%
Curative Resection
12%
Malnutrition
11%
ECOG Performance Status
11%
Resectability Status
11%
Cancer Care
11%
Older Adults
10%
KRAS mutation
10%
Team Assessment
10%
BRAF Wild Type
9%
Clinical Parameters
9%
Chemotherapy
9%
Treatment Response
9%
Patient Survival
9%
Population-based
8%
Lung
8%
Prognostic Role
8%
Conversion Therapy
8%
Colorectal Liver Metastases
8%
Primary Tumor
8%
Medicine and Dentistry
Metastatic Colorectal Cancer
81%
Overall Survival
54%
Colorectal Carcinoma
36%
Surgery
28%
Quality of Life
24%
Metastasectomy
24%
Systemic Therapy
23%
Malignant Neoplasm
23%
Cardiotoxicity
20%
Fluoropyrimidine
20%
Interleukin 6
20%
Carcinoembryonic Antigen
18%
Ablation Therapy
17%
Fluorouracil
16%
Metastatic Carcinoma
15%
Neoplasm
15%
Adjuvant Chemotherapy
14%
CA19-9
13%
Subgroup Analysis
13%
Capecitabine
13%
Survival Rate
13%
Geriatric Assessment
12%
Neoadjuvant Therapy
11%
Biological Marker
11%
Electrocorticography
10%
Oxaliplatin
10%
Liver Metastasis
9%
Disease Free Survival
9%
Frailty
8%
Conversion Therapy
8%
Primary Tumor
8%
Solid Malignant Neoplasm
7%
Hazard Ratio
7%
Treatment Response
6%
Computer Assisted Tomography
6%
Geriatric Syndrome
6%
Sex Hormone
6%
Cohort Study
6%
Hand Foot Syndrome
6%
Prospective Study
6%
Lung Cancer
6%
Melanoma
6%
Lymphocyte
6%
NMR Spectroscopy
6%
Intervention Study
6%
Neutrophil
6%
Medical Oncology
6%
Functional Status
6%
Hepatocellular Carcinoma
6%
Clinical Oncology
6%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
69%
Chemotherapy
46%
Overall Survival
41%
Colorectal Carcinoma
23%
Carcinoembryonic Antigen
20%
Neoplasm
20%
Cardiotoxicity
20%
Fluoropyrimidine
20%
Interleukin 6
20%
Oxaliplatin
20%
Fluorouracil
16%
Capecitabine
15%
Disease Free Survival
12%
Bevacizumab
12%
Solid Malignant Neoplasm
11%
Frailty
11%
Biological Marker
11%
Progression Free Survival
9%
Malignant Neoplasm
8%
Intervention Study
8%
Cohort Study
7%
Diseases
7%
Sex Hormone
6%
Rectum Cancer
6%
Hand Foot Syndrome
6%
Adjuvant
6%
Inflammation
6%
Neuroendocrine Tumor
6%
Liver Cell Carcinoma
6%
Circulating Tumor DNA
6%
C Reactive Protein
6%
Chemoradiation Therapy
6%
Functional Status
6%
Digestive System Cancer
6%
Head and Neck Cancer
6%
Colon Carcinoma
6%
Survival Rate
5%
Primary Tumor
5%
